<DOC>
	<DOCNO>NCT01673984</DOCNO>
	<brief_summary>The purpose study demonstrate treatment 6-monthly injection hormone therapy good well tolerated standard 3-monthly hormone therapy injection available treat prostate cancer . The study also aim answer whether doctor patient would prefer treatment 6-monthly injection rather injection every 3 month .</brief_summary>
	<brief_title>GP Extended Action Triptorelin</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>Patients must give write ( personally sign date ) inform consent complete study related procedure . Patients must 18 year old . Patients must document diagnosis locally advance metastatic prostate cancer suitable hormonal treatment Patients must medically castrate serum testosterone ≤ 0.5ng/mL Patients must receive least two injection 3 monthly LHRH agonist time screen test Patients must stable 3monthly LHRH agonist injection stable PSA level screen baseline ( i.e . baseline value must either low less 25 % high Screening value ≥25 % high , ≤0.5ng/mL high screen value ) . In addition : For patient locally advanced prostate cancer ( M0 ) , LHRH agonist injection ( formulation ) must initiate within last 3 year Baseline , For patient metastatic prostate cancer ( M+ ) Gleason score ≤ 7 , LHRH agonist injection ( formulation ) must initiate within last 2 year Baseline , For patient metastatic prostate cancer ( M+ ) Gleason score &gt; 7 , LHRH agonist injection ( formulation ) must initiate within last 12 month Baseline . Patients must estimate life expectancy least twelve month accord investigator 's assessment . Patients previous surgical castration present concomitant condition could compromise objective study and/or preclude protocoldefined procedure ( e.g . severe medical condition , brain metastasis , psychiatric disorder , active uncontrolled infection , know pituitary disease ) . Patients , opinion investigator , unable comply fully protocol study instruction . Patients receive investigational drug ( ) treatment ( ) within 30 day prior study entry require concurrent treatment experimental drug treatment present concomitant condition could compromise objective study and/or preclude protocoldefined procedure ( e.g . severe medical condition , brain metastasis , psychiatric disorder , active uncontrolled infection , know pituitary disease ) . Patients diagnosis cancer without history stability/remission within five year screen , exception nonmetastatic basal cell carcinoma . Patients currently take additional antiandrogen therapy part active hormonal control therapy . Patients schedule receive palliative radiotherapy course study . Patients receive LHRH agonist neoadjuvant radiotherapy adjuvant radiotherapy . Patients receive LHRH agonist adjuvant surgery . Patients schedule undergo radical prostatectomy course study . Patients know hypersensitivity LHRH agonist , analogue component product administer .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>